TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04485013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-080
Description: Variable dose (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-080
Description: Specified dose (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-080
Description: Specified dose (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-080
Description: Specified dose (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-080
Description: Specified dose (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-080
Description: Specified dose (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-080
Description: Specified dose (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-080
Description: Specified dose (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-080
Description: Specified dose (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Specified dose (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Specified dose (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Specified dose (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Specified dose (Q2W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Specified dose (Q2W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Specified dose (Q2W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Specified dose (Q2W)
Study: NCT04635982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape of the physical performance
Description: It has done a countermovement vertical jump, a twenty meter sprint and a kinesio tape application technique

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiotape of the physical performance
Description: It has done a countermovement vertical jump, a twenty meter sprint and a kinesio tape application technique
Study: NCT02605616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZ compound
Description: AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
Study: NCT04485013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTX-080
Description: Specified dose (Q2W)
Study: NCT02118714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrasentan
Description: Atrasentan
Study: NCT00840658

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Injection Risk Intervention
Description: This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared.
Study: NCT01719146

Intervention type: OTHER
Intervention: Specimen collection
Description: At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.

Intervention type: OTHER
Intervention: Specimen collection
Description: At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.

Intervention type: OTHER
Intervention: Specimen collection
Description: At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.
Study: NCT02945293

Intervention type: OTHER
Intervention: Oxycodone
Description: This study is interventional. Participants are given a single, one time administration of medication 10mg of oxycodone and observed
Study: NCT01112150

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NormaTec Pump
Description: Normatec Pump

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NormaTec Pump
Description: Normatec Pump
Study: NCT02666586

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Faba bean powder smoothie
Description: Breakfast smoothie with 32 g whole faba bean powder (300g).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faba bean powder smoothie
Description: Breakfast smoothie with 32 g whole faba bean powder (300g).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faba bean powder smoothie
Description: Breakfast smoothie with 32 g whole faba bean powder (300g).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faba bean powder smoothie
Description: Breakfast smoothie with 32 g whole faba bean powder (300g).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Faba bean protein concentrate smoothie
Description: Breakfast smoothie with 32 g faba bean protein concentrate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faba bean protein concentrate smoothie
Description: Breakfast smoothie with 32 g faba bean protein concentrate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faba bean protein concentrate smoothie
Description: Breakfast smoothie with 32 g faba bean protein concentrate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faba bean protein concentrate smoothie
Description: Breakfast smoothie with 32 g faba bean protein concentrate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Faba bean starch smoothie
Description: Breakfast smoothie with 33 g faba bean starch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faba bean starch smoothie
Description: Breakfast smoothie with 33 g faba bean starch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faba bean starch smoothie
Description: Breakfast smoothie with 33 g faba bean starch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faba bean starch smoothie
Description: Breakfast smoothie with 33 g faba bean starch.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Faba bean protein isolate smoothie
Description: Breakfast smoothie with 32 g faba bean protein isolate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faba bean protein isolate smoothie
Description: Breakfast smoothie with 32 g faba bean protein isolate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faba bean protein isolate smoothie
Description: Breakfast smoothie with 32 g faba bean protein isolate.
Study: NCT00840658

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lecture-format presentation
Description: 60 minute lecture-format presentation on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). There are no theory-driven active skill building elements oriented towards safer sex or safer injection.
Study: NCT02666586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Faba bean protein isolate smoothie
Description: Breakfast smoothie with 32 g faba bean protein isolate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-pulse smoothie smoothie
Description: Control smoothie with 32 g corn maltodextrin without added faba bean fractions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-pulse smoothie smoothie
Description: Control smoothie with 32 g corn maltodextrin without added faba bean fractions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-pulse smoothie smoothie
Description: Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
Study: NCT04207229

Intervention type: DEVICE
Intervention: CODMAN CERTAS Programmable Valves
Description: Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.
Study: NCT01167439

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper esophageal sphincter myotomy
Description: Upper esophageal sphincter release operation to allow better swallowing. The intervention is done under GA and by extra-mucosal approach.
Study: NCT03748251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the patients ate a pizza that fermented for 8 hours
Description: Patients eat pizza prepared with controlled ingredients but fermented 8 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the patients ate a pizza that fermented for 24 hours
Description: Patients eat pizza prepared with controlled ingredients but fermented 24 hours
Study: NCT00674128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate tissue adhesive (Dermabond)
Description: Skin closure will be performed with cyanoacrylate tissue adhesive.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyglactin 910 suture (Vicryl)
Description: Skin closure will be performed with polyglactin 910 suture.
Study: NCT00637533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar sympathetic block with Botulinum Toxin type A

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lumbar sympathetic block with Botulinum Toxin type A
Study: NCT02245503

Intervention type: DRUG
Intervention: Tamsulosin
Study: NCT03587129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: An anti-tumor Targeted drug
Study: NCT01808716

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy (808nm) and exercise
Description: Use of low-level laser therapy(LLLT)or placebo-LLLT applied on biceps brachii for muscle damage recovery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy (808nm) and exercise
Description: Use of low-level laser therapy(LLLT)or placebo-LLLT applied on biceps brachii for muscle damage recovery
Study: NCT00839098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instruction and Virtual Coach Group: Power seat function usage instruction- verbal, written, and virtual coach
Description: Subjects assigned to the Instruction \& Virtual Coach Group will be assigned to an Intervention Group Clinician and will receive the same training and instructional materials as the Instruction Group. Subjects will also be instructed in use of the virtual coach system, which will be active during the in-home usage periods to provide personalized feedback. As the Virtual Coach is a dynamic intelligent system, it will adjust its coaching to the needs of the individual. For example, if the person is compliant, the Virtual Coach will give positive feedback and then gradually transition to operating quietly in the background. If a person is not fully compliant, it will alter feedback modes (e.g., verbal cues, auditory tones, visual cues) and timing to attempt to increase compliance.
Study: NCT04317534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400mg IV
Study: NCT04210089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Contact Soft Cast
Description: The total contact soft cast will consist of wound dressing of choice to the ulcer and a plantar foot accommodative offloading felt pad for all foot ulcers, with 4x4 gauze pads added to the arch to create a rocker bottom for metarsophalangeal joint (MPJj) and plantar heel ulcers. The next layers will be:~* Unna boot from MPJs to just below the knee,~* Sterile Kerlix from MPJs to just below the knee~* Sterile 4 inch Kling wrap from the MPJs to just below the knee,~* Four inch coban from MPJs to just below the knee, and~* Ace wraps from MPJs to just below the knee

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Contact Soft Cast
Description: The total contact soft cast will consist of wound dressing of choice to the ulcer and a plantar foot accommodative offloading felt pad for all foot ulcers, with 4x4 gauze pads added to the arch to create a rocker bottom for metarsophalangeal joint (MPJj) and plantar heel ulcers. The next layers will be:~* Unna boot from MPJs to just below the knee,~* Sterile Kerlix from MPJs to just below the knee~* Sterile 4 inch Kling wrap from the MPJs to just below the knee,~* Four inch coban from MPJs to just below the knee, and~* Ace wraps from MPJs to just below the knee

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cam Boot
Description: Removable Diabetic cam boot will be used in patients willing and capable of using it. If patient does not want to use Diabetic cam boot then surgical shoe or regular shoe would be options.
Study: NCT01165801

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Cataract Surgery
Description: Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
Study: NCT03494725

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lpc-37
Description: Lacticaseibacillus paracasei Lpc-37 at 1.75 x 10\^10 colony forming units (CFU) per day, microcrystalline cellulose, magnesium stearate, silicon dioxide

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: microcrystalline cellulose, magnesium stearate, silicon dioxide
Study: NCT04283032

Intervention type: PROCEDURE
Intervention: Multiparametric magnetic resonance
Description: MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).

Intervention type: PROCEDURE
Intervention: Multiparametric magnetic resonance
Description: MRI uses a powerful magnetic field, pulsed radiofrequency and a computer to create detailed images of organs, soft tissues, bones, and practically the rest of the internal structures of the body. MRI does not use ionizing radiation (X-rays).
Study: NCT01172288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Description: 1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
Study: NCT02251223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir high dose
Study: NCT00816673

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo Circadin
Description: Placebo tabs of Prolonged release melatonin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Circadin
Description: prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
Study: NCT02255383

Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer Persona Total Knee System
Description: Primary Total Knee Arthroplasty
Study: NCT01083290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: single dose of one tablet; 25 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: single dose of one tablet; 25 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: single dose of one tablet; 25 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: single dose of one tablet; 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: single dose of one tablet; 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: single dose of one tablet; 50 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: single dose of one tablet; 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: single dose of one tablet; 100 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: single dose of one tablet; 100 mg tablet
Study: NCT04128215

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Period
Description: Participants completed an 8-week control period of normal lifestyle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Period
Description: Participants completed an 8-week control period of normal lifestyle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Period
Description: Participants completed an 8-week exercise intervention period of remotely supervised home-based non-weight-bearing all-extremity high intensity interval training (NWA-HIIT). NWA-HIIT consisted of 4x4-min bouts at 90% of maximal heart rate (HRmax) interspersed by 3x3-min bouts at 70% of HRmax. A 10-min warm-up and 5-minute cool-down at 70% of HRmax were included.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Period
Description: Participants completed an 8-week exercise intervention period of remotely supervised home-based non-weight-bearing all-extremity high intensity interval training (NWA-HIIT). NWA-HIIT consisted of 4x4-min bouts at 90% of maximal heart rate (HRmax) interspersed by 3x3-min bouts at 70% of HRmax. A 10-min warm-up and 5-minute cool-down at 70% of HRmax were included.
Study: NCT03297060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SSL Implementation Strategy
Description: Science to Service Laboratory (SSL) is an approach developed by the SAMHSA-funded Addiction Technology Transfer Centers (ATTCs) that consists of didactic training + performance feedback + leadership coaching to improve SBIRT adherence within the pediatric trauma center
Study: NCT04288531

Intervention type: DIETARY_SUPPLEMENT
Intervention: Iodine supplementation
Description: Recommendation, issued by the National Health Authorities, on supplementing with iodine (200 ug/day) women during preconception, pregnancy and lactation.
Study: NCT03769116

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single IV infusion of matching placebo

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: placebo
Description: Single IV infusion of matching placebo
Study: NCT03076164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib 1.5mg once daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 75mg once daily by mouth
Study: NCT03488823

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: with Flavanol
Description: Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: without Flavanol
Description: Patient will get twice daily drink without flavanols since one week before catheterization till one week after catheterization.
Study: NCT02333955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: 3 mg GCS-100 IV push. All doses of study drug will be administered least once monthly for a total of 1 year with a follow-up 4 weeks after the last dose is administered.
Study: NCT01821846

Intervention type: DRUG
Intervention: liraglutide
Description: Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).
Study: NCT03488823

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: without Flavanol
Description: Patient will get twice daily drink without flavanols since one week before catheterization till one week after catheterization.
Study: NCT02986880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of sodium chloride (NaCl) 9/1000
Study: NCT00842452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Patients receive oral topotecan hydrochloride on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Patients treated at the maximum tolerated dose undergo blood sample collection periodically on day 1 of course 1 for pharmacokinetic studies.